News

  • The Advisor Archive Feed

    The Congressional Budget Office recently issued a report stating that the federal budget will hit the debt limit and run out of cash early to mid-October. Some Congressional leaders have said they would like to vote on the budget and upcoming debt limit negotiations prior to the August recess. TSCL is fighting the proposal through national efforts from grass roots activists. To learn more, visit . .It pays to compare your options, but you need to do this soon, before the Medicare Open Enrollment period ends December 7th. For help shopping for a new drug or health plan locate Medicare benefit counselors in your area. Visit the State Health Insurance Program website — https://www.shiptacenter.org. .A report conducted by the Congressional Management Foundation claims that this year's budget will force House member offices to trim an additional 90,000 dollars in each office. A reduction to staff positions could mean decreased constituent services as responsibilities are shifted. … Continued

  • Dental Vision And Hearing Benefits May Also Be On The Chopping Block

    Misconceptions about Medicare coverage are very widespread. New beneficiaries and their families are frequently surprised when they learn what Medicare doesn't cover. Routine eye examinations, eyeglasses and lenses, hearing exams and hearing aids are among the services generally excluded from the core benefits covered by original Medicare. .TSCL Calls On Congress To Close The Loop Hole .The period covered by the Notch is a major area of dispute. When benefits are represented on a chart, the disparity forms a deep "V" notch. Benefits plunged from a peak for retirees born in 1916 and hit the lowest part of the "V" for those who were born in the years 1920-2Benefits began to rise for those born in 1922 until they became level with other retirees, starting with those born in 192See illustration below. … Continued

As the coronavirus continues to be among the major news stories each day, attention has turned to the drug supply in the U.S., not because of the cost but because of the vulnerability of the supply of prescription drugs for use in the nation. .TSCL acknowledges the fact that changes to programs like Social Security and Medicare will be necessary in the coming years, and we agree that changes should be made sooner rather than later to protect seniors from harsh benefit cuts. Our surveys show that seniors favor Social Security reform options that would require wealthier Americans to pay taxes on all of their earnings, and Medicare reform options that would better coordinate care and prioritize the prevention of fraud, waste, and abuse. .Three Bills Gain Cosponsors .Budget Conference Meets for First Time .Use the lowest price among other economically advanced countries – the so-called "favored nations rule" - to set what Medicare pays for certain drugs administered in a doctor's office, including many cancer medications. This would apply to the most expensive medications covered by Medicare's 'Part B,' which pays for outpatient care. .The battle between spending cuts versus revenue increases continues to be the largest point of contention between the two sides. Democrats are pushing a one-to-one ratio, contending that Congress has already outlined enough spending cuts in the debt limit increase law. If the Super Committee cannot come to a compromise by the deadline, mandated across-the-board budget cuts will occur. .The Consumer Price Index for Elderly Consumers (CPI-E) Act — Congressman John Garamendi (CA-3) introduced the bipartisan CPI-E Act in the 115th Congress, and in TSCL's December meeting with his office, he committed to re-introducing the bill once again in 201If adopted, his bill would enhance Social Security benefits by basing cost-of-living adjustments (COLAs) on an inflation index specifically for seniors. Under current law, COLAs are based on the way young, urban workers spend their money. .According to the committee's report, AbbVie has raked in more than 0 billion in net revenue from those two drugs since 2013, which the committee said was "driven in large part by AbbVie executives' decision to repeatedly raise the prices of Humira and Imbruvica." The company's top executives pocketed 0 million in compensation during that span, "much of which was directly linked to revenue increases," the report said. .The report goes on to say that "… the bill is fiercely opposed by Republicans and the powerful pharmaceutical industry, with executives warning it would harm innovation that leads to new drug development. The 50-50 split in the Senate is also raising questions about whether it could get through that chamber without losing any moderate Democrats."